Leptin is a 167-amino-acid, 16 kDa cytokine-like peptide hormone that circulates in proportion to total body fat mass. Its primary biosynthetic site is white adipose tissue, though the placenta, stomach mucosa, skeletal muscle, and certain immune cells also contribute measurable quantities. The hormone belongs to the long-chain helical cytokine superfamily and exerts its effects through the leptin receptor (LEP-R, also designated OB-R), a class I cytokine receptor expressed most densely in the hypothalamic arcuate nucleus. Binding activates the JAK2/STAT3 signal-transduction pathway, among others.
Physiologically, rising leptin concentrations accompany increases in adipose mass and are associated, in research models, with suppressed neuropeptide Y (NPY) and agouti-related peptide (AgRP) signalling , orexigenic pathways , alongside upregulation of pro-opiomelanocortin (POMC) and cocaine-and-amphetamine-regulated transcript (CART) neurons. The net effect observed in animal and in-vitro research is reduced energy intake and increased sympathetic outflow. A well-characterised phenomenon called leptin resistance, mechanistically analogous to insulin resistance, is documented in human obesity research; circulating leptin levels are often elevated rather than deficient in individuals with obesity, yet the expected downstream signalling is attenuated. The precise causal mechanisms remain an active area of investigation.
Congenital leptin deficiency , arising from homozygous loss-of-function mutations in LEP; is a rare monogenic cause of severe early-onset obesity documented in the clinical literature. Recombinant human leptin (metreleptin) is registered in several jurisdictions for the treatment of congenital leptin deficiency and certain lipodystrophy conditions; its regulatory status and approved indications vary by country. In Australia, prescribing is subject to the Therapeutic Goods Administration (TGA) Special Access Scheme (SAS) or Authorised Prescriber pathway for unapproved medicines where the product does not hold a current ARTG listing for the relevant indication. Any supply of leptin-related peptide products outside these regulatory mechanisms is illegal under Australian law.
Synthetic leptin analogues and "leptin-sensitiser" peptides are sometimes marketed in Australia outside approved therapeutic channels, particularly in the performance and body-composition space. The TGA has stated publicly that supplying unapproved biologics and peptide products without the appropriate regulatory approval is unlawful, and enforcement activity in this area is ongoing. Possession or supply of such products without a valid authorisation may constitute an offence under the Therapeutic Goods Act 1989 (Cth).
Sources: